3.21
Theories of Dissolution: Diffusion Layer Model
Dissolution, the process by which drug particles dissolve in a solvent, is explained by the diffusion layer model, a theoretical framework that simula…
Dissolution, the process of drug particles dissolving in a solvent, is explained by the diffusion layer model.
According to this model, initially, a thin layer saturated with the drug forms at the solid-liquid interface. Next, the soluble solute diffuses from the stagnant layer into the bulk solution.
According to Noyes-Whitney's equation, the dissolution rate depends upon the stagnant layer's diffusion rate, surface area, concentration, and thickness. The driving force for dissolution is the concentration gradient between the stagnant layer and the bulk solution.
Experimentally, to establish a robust in vitro to in vivo dissolution rate correlation, in vitro testing is performed at 37 degrees Celsius at a constant stirring rate to mimic body temperature and peristaltic movements in the GI tract.
In addition, sink conditions are maintained to avoid drug build-up in the bulk solution by adsorbing the dissolved drugs, increasing the volume of the solution, using fresh solvent at regular intervals, or partitioning the drug from the aqueous medium using an organic phase.
View the full transcript and gain access to JoVE Core videos
Q1: What is the diffusion layer model and how does it explain drug dissolution?
The diffusion layer model explains drug dissolution as a process occurring at the solid-liquid interface. A thin, drug-saturated layer forms at this boundary, and the solute diffuses from this stagnant layer into the bulk solution. This model provides a theoretical framework to simulate oral drug absorption and analyze experimental dissolution data.
Q2: What factors does the Noyes-Whitney equation identify as affecting dissolution rate?
The Noyes-Whitney equation identifies four key factors affecting dissolution rate: the diffusion rate through the stagnant layer, the drug's surface area, the concentration difference between the stagnant layer and bulk solution, and the thickness of the stagnant layer. These parameters collectively determine how quickly a drug dissolves in solution.
Q3: How does concentration gradient drive the dissolution process?
The concentration gradient between the drug-saturated stagnant layer and the bulk solution serves as the driving force for dissolution. A steeper concentration gradient results in a higher diffusion rate, as the solute moves from the region of higher concentration to lower concentration, continuing until equilibrium is reached.
Q4: Why is 37 degrees Celsius used in in vitro dissolution testing?
In vitro dissolution testing is conducted at 37 degrees Celsius to replicate normal human body temperature, establishing a robust correlation between laboratory results and in vivo drug behavior. Combined with constant stirring to simulate peristaltic movements in the gastrointestinal tract, these conditions create physiologically relevant testing conditions.
Q5: What are sink conditions and why are they maintained during dissolution testing?
Sink conditions maintain a low drug concentration in the bulk solution to sustain the concentration gradient and drive continuous dissolution. These conditions are achieved by adsorbing dissolved drugs, increasing solution volume, using fresh solvent at regular intervals, or partitioning the drug into an organic phase, preventing drug accumulation.
Q6: How does the stagnant layer thickness affect drug dissolution rate?
According to the Noyes-Whitney equation, stagnant layer thickness inversely affects dissolution rate. A thinner stagnant layer reduces the diffusion distance, allowing solute molecules to reach the bulk solution more rapidly and increasing the overall dissolution rate. This relationship is critical for predicting dissolution behavior.
Q7: What role does surface area play in the diffusion layer model of dissolution?
Surface area is a critical parameter in the Noyes-Whitney equation that directly influences dissolution rate. A larger drug particle surface area provides more contact between the solid and the saturated stagnant layer, allowing more solute molecules to diffuse simultaneously into the bulk solution and accelerating dissolution.